The FDA Sentinel Initiative - An Evolving National Resource

N Engl J Med. 2018 Nov 29;379(22):2091-2093. doi: 10.1056/NEJMp1809643.

Authors

Richard Platt¹, Jeffrey S Brown¹, Melissa Robb¹, Mark McClellan¹, Robert Ball¹, Michael D Nguyen¹, Rachel E Sherman¹

Affiliation

¹ From the Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston (R.P., J.S.B.); the Food and Drug Administration, Silver Spring, MD (M.R., R.B., M.D.N., R.E.S.); and the Duke Margolis Center for Health Policy, Durham, NC (M.M.).

PMID: 30485777
DOI: 10.1056/NEJMp1809643

No abstract available

MeSH terms

Adverse Drug Reaction Reporting Systems*
Computer Communication Networks*
Datasets as Topic*
Drug-Related Side Effects and Adverse Reactions / epidemiology
Humans
Product Surveillance, Postmarketing
United States
United States Food and Drug Administration*